TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Rating of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on TriSalus Life Sciences, with three buys, one hold and one sell among five analysts. The average 12-month price target is $10.20, while several firms recently set or raised targets to $12.00.
• TLSI shares opened at $4.32 and recently traded up 4.1%, with a market capitalization of approximately $266 million. The company reported a quarterly loss of $0.16 per share, in line with estimates, while revenue of $11.41 million exceeded expectations.
• Institutional ownership remains limited at 2.58%, although several firms—including Bank of New York Mellon, Deutsche Bank and Renaissance Technologies—recently initiated positions.

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have been given an average rating of "Hold" by the five analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $10.20.

TLSI has been the subject of several analyst reports. HC Wainwright upped their price target on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a "buy" rating in a research report on Wednesday, September 23rd. Guggenheim set a $12.00 price objective on TriSalus Life Sciences in a report on Wednesday, September 23rd. Wall Street Zen raised TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research note on Sunday, August 23rd. Weiss Ratings restated a "sell (e+)" rating on shares of TriSalus Life Sciences in a report on Friday, August 7th. Finally, Stifel Nicolaus set a $12.00 target price on TriSalus Life Sciences in a report on Wednesday, September 23rd.

TriSalus Life Sciences Trading Up 4.1%

Shares of TLSI opened at $4.32 on Friday. TriSalus Life Sciences has a fifty-two week low of $2.20 and a fifty-two week high of $7.95. The firm has a market cap of $266.03 million, a price-to-earnings ratio of -3.32 and a beta of 0.47. The firm has a 50 day moving average price of $4.90 and a 200-day moving average price of $4.32. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). The business had revenue of $11.41 million for the quarter, compared to the consensus estimate of $10.27 million. As a group, equities research analysts forecast that TriSalus Life Sciences will post -0.53 earnings per share for the current year.

Institutional Trading of TriSalus Life Sciences

A number of institutional investors have recently made changes to their positions in the stock. Cura Wealth Advisors LLC purchased a new position in shares of TriSalus Life Sciences in the second quarter worth $36,000. Renaissance Technologies LLC bought a new stake in TriSalus Life Sciences during the 1st quarter valued at $124,000. Deutsche Bank AG bought a new stake in TriSalus Life Sciences during the 2nd quarter valued at $221,000. Sei Investments Co. purchased a new stake in TriSalus Life Sciences during the 1st quarter valued at $275,000. Finally, Bank of New York Mellon Corp purchased a new stake in TriSalus Life Sciences during the 2nd quarter valued at $507,000. Hedge funds and other institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology company focused on developing technologies and therapies for patients with liver and pancreatic tumors. The company's approach combines investigational immunotherapies with drug-delivery technologies intended to improve treatment access to solid tumors, which can be difficult to reach through conventional systemic administration.

TriSalus is best known for its Pressure-Enabled Drug Delivery (PEDD) platform, which is designed to deliver medicines directly into tumors or their surrounding blood vessels by using controlled pressure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.